Literature DB >> 26119204

Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis.

Rex G Cheng1, Renuka Bhattacharya1, Matthew M Yeh2, Siddharth A Padia3.   

Abstract

PURPOSE: To describe full explant pathology and radiographic correlation in patients with hepatocellular carcinoma (HCC) treated with irreversible electroporation (IRE) who subsequently underwent liver transplant.
MATERIALS AND METHODS: In a retrospective study, 6 patients who had undergone IRE for HCC and subsequent orthotopic liver transplant during the period 2011-2013 were evaluated. Of the 6 patients, 4 had Child-Pugh class A cirrhosis, and 2 had class B cirrhosis. Irreversible electroporation was performed for a single focal HCC with median tumor diameter of 22 mm (range, 6-26 mm). After IRE, follow-up multiphasic cross-sectional imaging was performed at 1 month and every 3 months thereafter until liver transplant. Mean time between IRE and transplant was 10 months (range, 3-17 mo). Assessment of imaging response was based on modified Response Evaluation Criteria In Solid Tumors. Liver explants were evaluated for necrosis and viable carcinoma in IRE-treated tumors.
RESULTS: After IRE, all tumors showed a complete response on follow-up imaging. Five tumors showed complete pathologic necrosis without any viable carcinoma, sharply demarcated from the surrounding hepatic parenchyma. Bile ducts within the treatment area were preserved. A single tumor treated with a bipolar IRE probe had < 5% viable carcinoma cells at the periphery.
CONCLUSIONS: This study demonstrates the efficacy of IRE for HCC based on pathologic evaluation and correlation to radiologic findings.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26119204     DOI: 10.1016/j.jvir.2015.05.014

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  25 in total

1.  Irreversible electroporation for hepatic tumors.

Authors:  Maurizio Pompili; Giampiero Francica
Journal:  J Ultrasound       Date:  2019-03-06

2.  Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy.

Authors:  A Giorgio; F Amendola; A Calvanese; E Ingenito; B Santoro; P Gatti; E Ciracì; P Matteucci; V Giorgio
Journal:  J Ultrasound       Date:  2019-03-06

Review 3.  Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation.

Authors:  Wong Hoi She; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-14

Review 4.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

Review 5.  Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?

Authors:  Martina Coletta; Daniele Nicolini; Andrea Benedetti Cacciaguerra; Susanna Mazzocato; Roberta Rossi; Marco Vivarelli
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-27

Review 6.  Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum.

Authors:  Zlatko Devcic; Mohamed Elboraey; Lucas Vidal; Kabir Mody; Denise Harnois; Tushar Patel; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 7.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

8.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

9.  Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).

Authors:  Neal Bhutiani; Prejesh Philips; Charles R Scoggins; Kelly M McMasters; Melissa H Potts; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2016-05-01       Impact factor: 3.647

Review 10.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.